Quiroga, BorjaJose Soler, MariaOrtiz, AlbertoMartinez Vaquera, ShairaJarava Mantecon, Carlos JesusUseche, GustavoSanchez Marquez, Maria GabrielaCarnerero, ManuelJaldo Rodriguez, Maria TeresaMunoz Ramos, PatriciaRuiz San Millan, Juan CarlosToapanta, NestorGracia-Iguacel, CarolinaAguilar Cervera, Maria CintaBalibrea Lara, NoeliaLeyva, AlbaRojas, JoseGansevoort, Ron T.de Sequera, PatriciaSENCOVAC Collaborative Network2025-01-072025-01-072022-02-080931-0509https://hdl.handle.net/10668/25168Background Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. Methods Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. Results A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (PenantibodiesCOVID-19humoral responseSARS-CoV-2vaccineMessenger-rna-1273 sars-cov-2 vaccineresearch article34788858open access10.1093/ndt/gfab3131460-2385https://europepmc.org/articles/pmc8767866?pdf=render763962500001